FDA-cleared profile

Veuron-Brain-pAb3

Heuron Co., Ltd. · MRI · FDA-cleared (510(k))

Authorized purpose: Registration, fusion, display, and quantitative SUVR analysis of brain amyloid PET with MRI support to aid clinician assessment; outputs are reference information, not a stand-alone dementia diagnosis.

Clinical role
Multimodality registration, fusion, visualization, and quantitative amyloid PET analysis.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Calculated results are reference information to support professional assessment and are not a stand-alone diagnosis of dementia.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Registration, fusion, display, and quantitative SUVR analysis of brain amyloid PET with MRI support to aid clinician assessment; outputs are reference information, not a stand-alone dementia diagnosis.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Brain amyloid PET and supporting MRI images for the labeled tracer and disease workflow.
  • Who uses it?Intended users: Medical professionals assessing amyloid PET brain imaging.
  • What does the software produce?Output: Registered and fused images plus target-to-reference standard uptake value ratios and visualizations.
  • What is its most important limitation?Key limitation: Calculated results are reference information to support professional assessment and are not a stand-alone diagnosis of dementia.

Clinical takeaway. Clinical role: Registration, fusion, display, and quantitative SUVR analysis of brain amyloid PET with MRI support to aid clinician assessment; outputs are reference information, not a stand-alone dementia diagnosis.

Evidence takeaway. Evidence from the reviewed source record: Software verification and validation demonstrated the new functions perform as intended; no clinical testing was conducted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Registration, fusion, display, and quantitative SUVR analysis of brain amyloid PET with MRI support to aid clinician assessment; outputs are reference information, not a stand-alone dementia diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Multimodality registration, fusion, visualization, and quantitative amyloid PET analysis.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Brain amyloid PET and supporting MRI images for the labeled tracer and disease workflow.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Registered and fused images plus target-to-reference standard uptake value ratios and visualizations.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Medical-imaging workstations used for PET and MRI brain review.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Medical professionals assessing amyloid PET brain imaging.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Calculated results are reference information to support professional assessment and are not a stand-alone diagnosis of dementia.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
Software verification and validation demonstrated the new functions perform as intended; no clinical testing was conducted.
  • Exact FDA submission
  • Checked 2026-09-19

The exact 510(k) summary states the testing boundary and explicitly reports no clinical testing.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification and validation demonstrated the new functions perform as intended; no clinical testing was conducted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact 510(k) summary states the testing boundary and explicitly reports no clinical testing.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231642. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Brain amyloid PET and supporting MRI images for the labeled tracer and disease workflow.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K231642: Veuron-Brain-pAb3

  2. Routing

    Source context, not route validation: The cleared software is deployed through a medical-imaging workplace and organizes processing by radiotracer and disease workflow; local interfaces require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K231642: Veuron-Brain-pAb3

  3. AI processing

    Source context, not route validation: The exact FDA package describes Veuron-Brain-pAb3 as a software package that operates on off-the-shelf hardware, with a Linux (Ubuntu 18.04 LTS or higher) server and a Windows 10 or higher client, deployed via medical imaging workplaces. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software is deployed via medical imaging workplaces and is organized as a series of workflows which are specific to use with radio-tracer and disease combinations." … "Physical characteristics Software package Software package 02 Subject device Predicate device (K213801) Operates on off-the-shelf hardware Operates on off-the-shelf hardware (multiple vendors) (multiple vendors)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231642: Veuron-Brain-pAb3

  4. Returned objects

    Source context, not route validation: Registered and fused images plus target-to-reference standard uptake value ratios and visualizations.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K231642: Veuron-Brain-pAb3

  5. Viewer/worklist/report

    Unresolved route: Registered and fused images plus target-to-reference standard uptake value ratios and visualizations.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K231642: Veuron-Brain-pAb3

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Veuron-Brain-pAb3 as a software package that operates on off-the-shelf hardware, with a Linux (Ubuntu 18.04 LTS or higher) server and a Windows 10 or higher client, deployed via medical imaging workplaces. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software is deployed via medical imaging workplaces and is organized as a series of workflows which are specific to use with radio-tracer and disease combinations." … "Physical characteristics Software package Software package 02 Subject device Predicate device (K213801) Operates on off-the-shelf hardware Operates on off-the-shelf hardware (multiple vendors) (multiple vendors)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The cleared software is deployed through a medical-imaging workplace and organizes processing by radiotracer and disease workflow; local interfaces require confirmation.
  • Exact FDA submission
  • Checked 2026-09-08

Current product-family workflow context

Heuron identifies Veuron-Brain-pAb3 in its product history and separately reports organization-level security certifications; those certifications are not treated as exact-release assurance.

product family · checked 2026-09-08

Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231642
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication states that the software processes multiple modalities including MRI and PET; MRI alone is too narrow. Controlled directory display reconciled from exact FDA wording: MRI and PET -> MRI.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-10-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor company page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K231642 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K231642: Veuron-Brain-pAb3

    U.S. Food and Drug Administration - Published 2023-10-13 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. openFDA exact recall query for K231642

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  7. Heuron company and product history

    Heuron - Accessed 2026-09-08

    Scope: productFamily, regulatoryHistory, vendorWideSecurity

Research history

  1. K231642 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history